FDA approved Fruzaqla (fruquintinib), an oral targeted therapy for adults with metastatic colorectal cancer who have been previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if RAS wild-type and medically appropriate, an anti-EGFR therapy.Â
FDA revised the existing indication of Keytruda (pembrolizumab) with trastuzumab, fluoropyrimidine, and platinum-containing chemotherapy for the first-line treatment of patients with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma.Â
Cancer Research UK and the KWF Dutch Cancer Society, have entered a multi-project strategic partnership to advance promising therapeutic agents for cancer through early clinical development.
Imatinib—the pathbreaking cancer drug that gave Philadelphia chromosome-positive chronic myeloid leukemia patients near-normal life expectancies—now stands poised to save even more lives.Â
Lung Cancer Awareness Month kicked off this week, and this is a monumental one for us at the American Cancer Society.
The ECOG-ACRIN Cancer Research Group has renamed its Group Meeting Attendance Awards for Minority Trainees to the Edith Peterson Mitchell, MD Health Equity Travel Scholarships.
Anthony Faber, a professor in the Philips Institute for Oral Health Research at the Virginia Commonwealth University School of Dentistry and Massey Comprehensive Cancer Center, has received four grants totaling more than $6.3 million to aid in the development of new targeted therapies for neuroblastoma and synovial sarcoma.Â
Patrick M. Reagan, associate professor of medicine, was named director of the Blood & Marrow Transplant and Cellular Therapies program at Wilmot Cancer Institute at University of Rochester Medical Center.
Fayez Estephan was named assistant professor of medicine in the Division of Hematology and Oncology at George Washington University Cancer Center and GW School of Medical and Health Sciences.Â
Jennifer Vaz joined the George Washington University Cancer Center and the GW Medical Faculty Associates as a gynecological oncologist.Â
